๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Hemorrhagic events in hepatocellular carcinoma patients treated with antiangiogenic therapies

โœ Scribed by Duffy, Austin; Wilkerson, Julia; Greten, Tim F.

Book ID
120003952
Publisher
John Wiley and Sons
Year
2013
Tongue
English
Weight
664 KB
Volume
57
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Can we develop effective combination ant
Can we develop effective combination antiangiogenic therapy for patients with hepatocellular carcinoma?
โœ Justin B. Wenger; Napoleon Santos; Yanxia Liu; Jennifer Dallas; Sukanthini Subbi ๐Ÿ“‚ Article ๐Ÿ“… 2011 ๐Ÿ› PAGEPress Publications ๐ŸŒ English โš– 251 KB

Antiangiogenic therapy has shown promise in the treatment of patients with hepatocellular carcinoma (HCC). Bevacizumab, sorafenib, and sunitinib showed efficacy in patients with HCC; and sorafenib is approved by the FDA for treatment of this cancer. In practice, the clinical benefit of these agents

Further experience in treating patients
Further experience in treating patients with hepatocellular carcinoma in Uganda
โœ Charles L. M. Olweny; Edward Katongole-Mbidde; Silver Bahendeka; David Otim; Jus ๐Ÿ“‚ Article ๐Ÿ“… 1980 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 728 KB

One hundred and thirty nine patients with histologically proven hepatocellular carcinoma (HC) were admitted to the Uganda Cancer Institute for treatment. The patients were considerably younger and seemed to have more advanced disease than HC patients in Europe and in North America. Of the 99 evaluab